The aim of the pilot retrospective study was to implement PATS in the process of evaluation of pharmacotherapy of hospitalized diabetics. In 3-months cycles, collected data on pharmacotherapy were compared with clinical guidelines and hospital formulary.
PES1

COST OF ILLNESS OF GLAUCOMA IN CANADA: ANALYSES BASED ON VISUAL FIELD MEASUREMENTS AND PHYSICIAN'S ASSESSMENT
Patients were identified using ICD-9 code 365.11. Threeyear data associated with POAG were collected from patient charts in two clinics by a reviewer using a data collection form. A second reviewer verified data entry, including visual field (VF) mean deviation (MD), physician's assessment (PA), and resource utilization (physician visits, procedures, and medications). VF was classified mild (MD < 5 dB), moderate (5 ≥ MD < 12 dB), or severe (MD ≥ 12 dB); and PA as stable, uncontrolled, or delayed stable (uncontrolled for 12 months, then stable). Resources were costed in Canadian dollars from the Ministry of Health perspective using standard lists. Costs were summed for each patient, then contrasted between groups using ANOVA with Scheffe's post-hoc test (a = 0.05). RESULTS: Of 411 patient charts extracted, 235 provided useable data (mean follow-up 4 years); 35 excluded patients had ocular comorbidities, 141 had insufficient follow-up data (<3 years). Mean costs (SD) for VF groups mild (n = 80), moderate (n = 81), and severe (n = 74) were $376 ($279), $493 ($314), and $586 ($251), respectively. Analysis by PA for stable (n = 115), uncontrolled (n = 62), and delayed stable (n = 58) yielded costs of $437 ($269), $506 ($320), and $547 ($306), respectively. In the VF analysis, differences were significant (p < 0.05) between all groups for the first half of the follow-up period and between mild and severe for the entire follow-up period. For PA, the mean cost of the stable group was the lowest, without however significant differences. DISCUSSION and CONCLUSIONS: The cost of treating POAG increases with severity, especially when applying VF categories. Hence, severity in terms of VF score may give an indication of the magnitude of the expected total cost. Further examination of the relationship between VF and other clinical parameters, such as intra-ocular pressure, is warranted. 
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MEDICAL PREDICTIVE FACTORS OF GLAUCOMA TREATMENT COSTS IN FRANCE
OBJECTIVES:
To describe the patterns and the economics of glaucoma treatment. METHODS: Ophthalmologists selected at random had to include 4 consecutive patients older than 18 seen in consultation during a week, 2 with glaucoma and 2 with ocular hypertension (OH). Socio-demographics, general and eye comorbidities, glaucoma risk factors, clinical data, and medical item consumption over the previous 5 years were collected. The economic perspective was society's. Predictive medical factors of costs were identified using a stepwise regression. RESULTS: 84 ophthalmologists included 337 patients who were 60% female with a mean age of 62; 34.1% had OH and 35.9% were still receiving first line treatment. Glaucoma patients were older and no difference was found on confounding factors. Patients with
